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Abstract
Background: Recent research show that polycystic ovary syndrome (PCOS) may have an association with low-
grade chronic inflammation, IL-18 is considered as a strong risk marker of inflammation.
Methods: To investigate serum IL-18 concentrations in PCOS patients and focus on its relationship between
obesity and insulin resistance (IR). Sixty consecutive women with PCOS and thirty controls were recruited. Serum
level of IL-18 and fasting blood glucose, fasting insulin, follicle-stimulating hormone (FSH), luteinizing hormone (LH)
and testosterone (T) were measured.
Results: Serum levels of IL-18 was significantly higher in the PCOS group than in the control group. Serum level of
IL-18 was higher in the PCOS group with IR than in the PCOS group without IR. Serum level of IL-18 was higher in
obese PCOS patients than in lean PCOS patients. Serum level of IL-18 was higher in lean PCOS patients than in the
lean control group. Serum level of IL-18 in the PCOS group was positively related to BMI, IR index and T.
Conclusion: IL-18 level was increased in PCOS patients, and correlated with insulin resistance, obesity and
hyperandrogenism.
Background
Polycystic ovary syndrome (PCOS) is a common and
complex endocrine disorder of women in their repro-
ductive years, with prevalence between 5% and 10%
[1,2]. PCOS is characterized by chronic anovulation,
hyperandrogenism, and insulin resistance (IR) [3]. Addi-
tionally, PCOS is often associated with obesity and a
subsequent increased risk for type 2 diabetes [4-6].
Women with PCOS may have chronic low-level inflam-
mation. Kelly et al [7] have reported increased serum
C-reactive protein (CRP) level in PCOS patients. Amato
et al [8] found that serum and follicular fluid interleu-
kin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a)
v a l u e sw e r eh i g h e ri nP C O Sw o m e nt h a ni nc o n t r o l s .
Interleukin-18 (IL-18) is a proinflammatory cytokine
that induces the production of TNF-a [9], which in turn
promotes the synthesis of IL-6 [10], and IL-6 regulates
the synthesis of CRP in the liver [11]. Like IL-6 and
CRP, IL-18 is considered a strong risk marker of cardio-
vascular death [12]. In order to investigate the possible
roles of IL-18 in the pathogenesis of PCOS, we studied
the serum level of IL-18 in PCOS patients, as well as it’s
correlation with IR, obesity and hyperandrogenism.
Methods
Patients and control group
A total of 60 patients with PCOS were included in this
prospective, case-controlled study. We analyzed data
from women with PCOS who visited the Department of
Obstetrics and Gynecology, Division of Reproductive
Center, Peking University Third Hospital, Beijing, from
October 2006 to January 2007. The diagnosis of PCOS
was based on the 2003 Rotterdam ESHRE/ASRM cri-
teria: (1) oligo- and/or anovulation; (2) clinical and/or
biochemical signs of hyperandrogenism (patients pre-
sented with hirsute, acne or alopecia, and/or increased
circulating levels of testosterone; (3) polycystic ovaries
(ovarian morphology was assessed using transvaginal
ultrasound), and exclusion of other aetiologies (congeni-
tal adrenal hyperplasia, androgen-secreting tumors,
Cushing’s syndrome) [13-15]. Women who had received
any hormonal treatment or insulin-lowering agent dur-
ing the last 3 months were excluded from the study.
The control group consisted of 30 subjects, the con-
trols were selected from women attending the clinic on
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menstrual cycle and normal androgen level and were
taking no medication. All patients were Chinese and
had not taken hormonal medications, including contra-
ceptive pills, for the last 6 months. None of the patients
had clinical evidence (history or examination) of recent
or ongoing infection. Institutional Review Board
approval was obtained for this study and patients’ con-
sent was obtained from all women prior to inclusion in
the study.
Firstly, the PCOS patients were divided into two sub-
groups PCOS IR group and PCOS without IR group,
insulin resistance was judged by using the homeostatic
model index (HOMA-IR), and 2.69 was selected as a
cutoff point [16,17]. Thirty cases of PCOS with insulin
resistance (HOMA-IR ≥2.69), thirty cases of PCOS with-
out insulin resistance (HOMA-IR < 2.69).
Secondly, the PCOS patients were divided into obese
PCOS patients and lean PCOS patients. The diagnosis of
obesity was based on the criteria of Asia-Oceania[18],
which was defined by a BMI greater than or equal to
25 kg/m
2. Twenty-nine cases of obese PCOS (BMI ≥2.5 kg/
m
2) and thirty-one cases of lean PCOS (BMI < 2.5 kg/m
2).
Blood samples were obtained between days 2 and 3 of
the menstrual cycle. In patients with amenorrhea, bleed-
ing was induced by progestogen and blood samples
were taken thereafter. If no bleeding occurred, blood
samples were taken after excluding pregnancy by a com-
mercially available pregnancy test. Blood was taken from
the antecubital vein after a 12-hours overnight fasting.
Samples were immediately centrifuged, and serum was
separated and frozen at -20°C until assayed.
Body Mass Index (BMI) was calculated as follows:
weight (kilograms)/height
2 (meters). Homeostasis model
assessment index for IR (HOMA-IR) was calculated as
follows: fasting insulin (mIU/l) × fasting glucose (mmol/
L)/22.5.
IL-18 enzyme-linked immunosorbent assay (ELISA)
Serum was separated and frozen at -20°C until assayed.
Fasting insulin (FIN), follicle- stimulating hormone
(FSH), luteinizing hormone (LH) and testosterone (T)
levels were determined by chemiluminescence-immu-
noassay (CLIA) and fasting glucose (FBG) levels were
detected using the glucose oxidase method. Serum IL-18
levels were measured using ELISA (Human IL-18 ELISA
Kit, Bender MedSystems. Ltd., Vienna, Austria) with a
lower limit of detection of 9.2 pg/mL and mean intra-
and interassay coefficients of variation of 6.5 and 8.1%,
respectively.
Statistical analyses were performed using SPSS 11.5
(SPSS Inc., Chicago, IL), with P < 0.05 being considered
statistically significant. We analyzed the difference of
serous components in three groups by correlation analy-
sis, and the correlation between the levels of these ser-
ous components by linear regression analysis.
Results
The mean level of IL-18 in PCOS IR group was 243.1
pg/mL (S.D. = 64.2), in the PCOS without IR group the
mean level was 174.3 pg/mL (S.D. = 66.8) and in the
control group the mean level was 122.4 pg/mL (S.D. =
40.2). Serum IL-18 concentrations were increased in
PCOS patients irrespective of the presence or absence of
IR, and PCOS women with IR presented with increased
IL-18 level than PCOS without IR. PCOS patients pre-
sented with increased LH, T, HOMA-IR and LH/FSH
levels, especially in PCOS group with IR, and there was
a statistically significant difference (P < 0.05) (Table 1).
The mean level of IL-18 in obese PCOS women was
247.5 pg/mL (S.D. = 63.6), in the lean PCOS women the
mean level was 172.5 pg/mL (S.D. = 64.0) and in control
group the mean level was 122.5 pg/mL (S.D. = 40.2).
Serum IL-18 concentration was increased in PCOS
patients irrespective of the presence or absence of
Table 1 Comparison of plasma biochemical variables in PCOS with insulin resistance(IR) group, PCOS without insulin
resistance group and controls
PCOS with IR (n = 30) PCOS without IR (n = 30) Controls (n = 30)
Age(year) 28.4 ± 3.8 28.2 ± 3.4 28.4 ± 3.9
BMI(kg/m
2) 27.0 ± 3.8 22.5 ± 3.7 21.3 ± 2.3
FBG(mmol/L) 5.1 ± 0.7
Δ 4.7 ± 0.5 5.0 ± 0.6
FINS(uIU/ml) 20.5 ± 3.1*
Δ 7.1 ± 2.9 6.2 ± 3.1
FSH(IU/L) 6.1 ± 1.5* 6.2 ± 1.7* 6.9 ± 1.2
LH(IU/L) 11.5 ± 4.7* 9.7 ± 4.8* 4.5 ± 1.9
T(nmol/L) 1.9 ± 0.7*
Δ 1.6 ± 0.5* 1.1 ± 0.5
Homa IR 4.6 ± 1.7*
Δ 1.5 ± 0.6 1.4 ± 0.8
LH/FSH 1.9 ± 0.8*
Δ 1.4 ± 0.5* 0.7 ± 0.3
IL18 (pg/ml) 243.1 ± 64.2*
Δ 174.3 ± 66.8* 122.4 ± 40.2
Values are given as means ± SD.
*Compare with controls, P < 0.05;
Δcompared with PCOS patients without IR, P < 0.05.
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with higher IL-18 level than lean PCOS patients (P =
0.000). Obese PCOS women presented with increased
fasting insulin, LH, T, HOMA-IR and LH/FSH, com-
pared with lean PCOS women. The mean level of IL-18
in lean controls was 118.6 pg/mL (S.D. = 34.9). Serum
IL-18 concentration was high e ri nl e a nP C O Sp a t i e n t s
than in controls (P = 0.000). Serum level of fasting insu-
l i n ,L H ,T ,H O M A - I Ra n dL H / F S Hw e r eh i g h e ri n
P C O Sw o m e nt h a ni nc o n t r o l sw i t hn o r m a lB M I ,a n d
there was a statistically significant difference (P < 0.05)
(Table 2).
Serum IL-18 concentrations was correlated with BMI
(r = 0.688, P = 0.000), HOMA-IR (r = 0.599, P = 0.000),
T (r = 0.602, P = 0.000) and LH/FSH (r = 0.468, P =
0.000) (Figures 1, 2, 3 and 4).
Linear regression analysis, including serum IL-18 con-
centration as the dependent variable and stepwise (prob-
ability of F to enter ≤ 0.05; probability of F to remove ≥
0.10) introduction of BMI, HOMA-IR, T levels and LH/
FSH as independent variables, showed that HOMA-IR,
BMI and T determined 54.7% serum IL-18 concentration,
[ I L - 1 8=-3 4 . 7 0 8+9 . 0 2 2×H O M A - I R+6 . 6 9 2×B M I
(kg/m
2) + 29.066 × T (nmol/L); R
2 =0 . 5 4 7 ;F=2 4 . 7 4 5 ;
P = 0.000], whereas LH/FSH was removed from the
regression equation. Therefore, serum IL-18 levels appear
to be determined by BMI, T and IR, and serum level of T
seemed to be the most important influencing factor.
Discussion
IL-18 was first described as an IFN-g inducing factor,
and has multiple functions which include of the synth-
esis of IFN-g by T cells and NK cells, promotion of
Th1-type immune response, augmentation of prolifera-
tive response and cytokine production of activated T
cells. Meanwhile, IL-18 leads to activities against patho-
gens, by activating effector cells involved in the cellular
interactions that occur during inflammation [19,20]. In
our study, serum IL-18 concentration was increased in
PCOS patients irrespective of the presence or absence of
IR and obesity. Therefore, the PCOS disease per se has
correlation with IL-18, not dependent on IR and obesity.
In our study, PCOS patients complicated with IR and
obesity presented with increased IL-18 level, and serum
IL-18 concentration had positive correlation with IR and
Table 2 Comparison of serum biochemical variables and inflammatory markers between obese PCOS women and lean
PCOS women and lean controls
Obese PCOS (n = 29) Lean PCOS (n = 31) Lean controls (n = 29)
Age (year) 28.3 ± 2.4 28.1 ± 3.0 28.0 ± 2.7
BMI(kg/m
2) 28.0 ± 2.8 22.1 ± 3.4 21.0 ± 2.0
FBG (mmol/L) 5.1 ± 0.7* 4.9 ± 0.5
Δ 5.0 ± 0.5
FINS (uIU/ml) 16.8 ± 8.9* 11.0 ± 7.6
Δ 6.1 ± 3.1
FSH (IU/L) 6.3 ± 1.4 6.0 ± 1.7
Δ 7.0 ± 1.2
LH (IU/L) 12.3 ± 4.8* 9.1 ± 4.3
Δ 4.6 ± 2.0
T (nmol/L) 2.0 ± 0.7* 1.5 ± 0.5
Δ 1.1 ± 0.5
Homa IR 4.1 ± 2.1* 2.1 ± 1.4
Δ 1.4 ± 0.7
LH/FSH 1.9 ± 0.6* 1.4 ± 0.6
ΔΔ 0.7 ± 0.3
IL18 (pg/ml) 247.5 ± 63.6* 172.5 ± 64.0 118.6 ± 34.9
Values are given as means ± SD.
*Compare with lean PCOS, P < 0.05;
Δcompared with lean controls P < 0.05.
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Figure 1 Correlations of serum IL-18 concentrations with body
mass index(BMI).
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Figure 2 Correlations of serum IL-18 concentrations with Homa
IR.
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Page 3 of 5BMI, it seemed that IR and obesity may accelerate the
increase of serum IL18 level. The correlation of IL-18
level with BMI observed in our study also suggested
that IL-18 might be produced by adipose tissue. In
2004, Escobar-Morreale et al [21] had reported that
PCOS and obesity induced an increase in serum IL-18
levels, which was also associated with several indexes of
global and visceral adiposity and with IR. IL-18 secretion
by adipose tissue has been explored or reported else-
where, but the mechanism needs to be addressed by
future studies.
In our series, IL-18 concentration had positive correla-
tion with T, and linear regression analysis showed that
serum IL-18 concentration was determined by T, BMI
and HOMA IR, but especially by T. Moreover, it seemed
that hyperandrogenism was correlated with serum level
of IL-18, and it is a crucial factor of increased level of
IL-18, which might be the reason for PCOS patients
who without insulin resistance and obesity have elevated
IL-18, but the mechanism of it has not been clear, it
need future study.
Mounting evidence suggests that IL-18 is involved in
the pathogenesis of obstertrical disease and metabolic
syndrome. Recently study showed that increased serum
level of IL-18 was observed in preeclampsia [22], prema-
ture rupture of membranes, acute fatty liver of preg-
nancy and fetal growth restriction [23]. So IL-18 maybe
paly an important role in pregnancy. Futhermore, some
recent reports showed that IL18 might be correlated
with atherosclerosis [24] and served as a cardiovascular
risk marker [25,26]. Although the definite demonstration
of increased cardiovascular morbidity and mortality in
PCOS women is still pending by now [27], cardiovascu-
lar risk factors cluster in these patients [28], and
increased prevalence of coronary artery calcification
[29], carotid atherosclerosis [30], and impairment in car-
otid viscoelastic properties [31] have been reported in
PCOS. Therefore, the increase of serum IL-18 concen-
tration in PCOS patients might be due to the presence
of subclinical atherosclerosis in these women.
In summary, the serum IL18 level was increased in
PCOS patientsl, and correlaed with IR, obesity and
hyperandrogenism. Moreover, since IL18 was a proin-
flammatory cytokine and a strong risk marker for cardi-
ovascular disease, whether we can use anti-inflammatory
drug to reduce the serum level of IL18 and consequently
decrease the incidence of PCOS, which may shred a new
light on prevention or treatment of PCOS, but it is still
need be further investigated based on large population.
Conclusion
IL-18 level was increased in PCOS patients, and correlated
with insulin resistance, obesity and hyperandrogenism.
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